{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:18:29Z","timestamp":1783613909343,"version":"3.55.0"},"reference-count":27,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"abstract":"<jats:p>Background: Peptide receptor radionuclide therapy (PRRT) is an established treatment for somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), with eligibility determined by the Krenning score. While SSTR PET provides greater sensitivity than octreotide scintigraphy, its impact on PRRT eligibility remains unclear. We compared Krenning scores between [111In]octreotide scintigraphy and [68Ga]DOTATOC PET and assessed eligibility under NETTER-1 and NETTER-2 criteria. Methods: We retrospectively assessed tumor Krenning scores in 115 patients with well-differentiated GEP-NETs who underwent both [111In]octreotide scintigraphy and [68Ga]DOTATOC PET. PRRT eligibility was defined according to NETTER-1 (Krenning \u22652) and NETTER-2 (Krenning \u22653) criteria. Logistic regression identified predictors of Krenning \u22653 on SSTR PET. Quantitative PET analysis was performed for patients with positive baseline [68Ga]DOTATOC PET scans. Results: Median Krenning scores were higher with SSTR PET than planar imaging (3 [IQR 3\u20134] vs. 2 [IQR 0\u20133], p &lt; 10\u22128). NETTER-1 eligibility increased from 59.1% with planar imaging to 81.7% with PET (p &lt; 10\u22123), and NETTER-2 from 48.7% to 76.5% (p &lt; 10\u22124). Among patients eligible on planar imaging, 95.6% (NETTER-1) and 98.2% (NETTER-2) had concordant PET findings. Conversely, 61.7% (NETTER-1) and 55.9% (NETTER-2) of patients ineligible on planar imaging were reclassified as eligible with PET. Metastatic disease was associated with higher SSTR PET uptake (odds ratio 9.5 [95% confidence interval: 2.7\u201332.8], p &lt; 10\u22123). SUV&lt;sub&gt;max&lt;\/sub&gt; discriminated patients with Krenning \u22653 using an optimal threshold of 9.2 (AUC 0.93). Conclusions: [68Ga]DOTATOC PET yields higher Krenning scores and increases PRRT eligibility compared with [111In]octreotide scintigraphy. PET may be unnecessary for clearly positive planar studies but identifies additional candidates with borderline or negative planar results.<\/jats:p>","DOI":"10.1159\/000552968","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:01:14Z","timestamp":1781280074000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of [\n                    <sup>111<\/sup>\n                    In]octreotide Scintigraphy and [\n                    <sup>68<\/sup>\n                    Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility"],"prefix":"10.1159","author":[{"given":"Roberto","family":"Fedrigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-6982","authenticated-orcid":false,"given":"Sara","family":"Harsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Murtha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-7765","authenticated-orcid":false,"given":"Joao Paulo","family":"Solar Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Benard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Loree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251512"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39607-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnae022"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2003.11.008"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.035667"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.165803"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-010-0383-9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0987"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0317-x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050034"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4330"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1935-5"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.206631"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1148\/rg.352140164"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09518-y"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000475526"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ph12030114"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223016"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00701-3"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020451"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.10.018"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3413\/Nukmed-0613-13-07"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.091165"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.18.19881"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0393"}],"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:00:58Z","timestamp":1783612858000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1159\/000552968","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.32646933","asserted-by":"subject"}]},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}